Rezolute rises; co's hypoglycemia drug meets trial goal
** Rezolute RZLT.O shares jumps 11.3% to $4.40 premarket
** The drug developer says its experimental treatment ersodetug met the main goal of a late-stage study in patients with tumor-related hyperinsulinism
** The rare condition can cause dangerously low blood sugar
** RZLT says 13 of 16 enrolled patients cut their need for intravenous glucose by at least half, including 12 who were able to stop the treatment entirely
** Expects full results from completed study by mid-December
** Treatment generally well tolerated so far, with no safety issues
** As of last close, RZLT stock was up ~64% YTD